Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fructooligosaccharide + Lactobacillus crispatus 197 + Lactobacillus gasseri CCFM1201 is a synbiotic combination product designed to support women's vaginal health. It combines a prebiotic (fructooligosaccharide) with two strains of probiotic bacteria. Fructooligosaccharides (FOS) are non-digestible fibers that act as a food source for beneficial bacteria, promoting their growth and activity. *Lactobacillus crispatus* is a key species for a healthy vaginal microbiome, known to produce lactic acid which helps maintain an acidic environment (pH < 4.5) that is inhospitable to pathogens. [10, 14] The specific strain *Lactobacillus gasseri* CCFM1201 has been studied for its ability to inhibit *Gardnerella vaginalis*, the primary pathogen associated with bacterial vaginosis (BV). [13] In preclinical models, *L. gasseri* CCFM1201 has been shown to inhibit biofilm formation, modulate local immune responses by reducing pro-inflammatory cytokines, and help restore the structure of vaginal tissue. [1, 12, 13] This combination aims to restore and maintain a healthy vaginal flora, thereby preventing and managing vaginal dysbiosis such as bacterial vaginosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fructooligosaccharide + lactobacillus crispatus 197 + lactobacillus gasseri CCFM1201.